Half Yearly Report and Accounts

Half-year financial report - 31 December 2025

Key Highlights

● Significant improvements in H1 FY26 as revenue increased 8% to $12.9 million

● Gross margin improved 9.4 percentage points on corresponding prior period to 32.1%

● Business reached operating breakeven in Q2 FY26

Wellnex Life Limited (ASX/AIM: WNX) ("Wellnex Life" or the "Company") Executive Chairman, Ash Vesali is pleased to provide the following update along with Wellnex Life's half-year financial report for the six months ended 31 December 2025 (unaudited).

During the period, the Company began a strategic turnaround focused on transitioning to a leaner and more efficient operation with stronger management processes and tighter capital management. As a result, gross margin during the period increased to 32.1%, reflecting improved cost control and operational efficiency. Importantly, the Group finished Q2 FY26 operating at breakeven, providing positive momentum heading into the second half of FY26.

Following the period end, the Company is reviewing funding options to raise capital, including towards settlement of related parties loans.

In H2 FY26, the Company remains focused on delivering consistent performance with a goal of building long-term shareholder value.

--- END ---

For further information, please contact:

Wellnex Life Limited (ASX/AIM:WNX) Reach Markets

Ash Vesali T: 1300 805 941

Executive Chairman E: [email protected]

E: [email protected]

UK Investors

Strand Hanson (Financial & Nominated Advisor)

James Harris / Richard Johnson Tel: +44 (0) 20 7409 3494

Orana Corporate LLP (Joint Broker) [email protected]

Sebastian Wykeham

S.P. Angel Corporate Finance LLP (Joint Broker) Tel: +44 (0)20 3470 0470

David Hignell / Vadim Alexandre

To learn more, please visit: https://wellnexlife.com.au/

The information contained within this announcement is deemed by the Company to constitute inside information pursuant to article 7 of EU Regulation 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 as amended.

1. Company details

2. Results for announcement to the market

Dividends

There were no dividends paid, recommended or declared during the current financial period.

Financial Performance Revenue for the period was $12.919 million, an increase of 8.0% on the prior corresponding period (31 December 2024: $11.962 million), with brand sales comprising 72.3% of the total revenue with the balance coming from IP licensing. During the period, the Company commenced a strategic turnaround program focused on transitioning to a leaner and more agile operating model. This initiative includes the implementation of an enhanced management framework and disciplined capital management. As result for the period gross margin increased to 32.1%, an increase of 9.4% on the prior corresponding period. The Group closed Q2 FY26 operating at breakeven, providing a solid platform entering 2HFY26 The Company continues to focus on revenue growth in 2HFY26 and remains focussed on delivering consistent performance with the goal of creating long-term shareholder value.  

3. Net tangible assets

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividends

Current period

There were no dividends paid, recommended or declared during the current financial period.

Previous period

There were no dividends paid, recommended or declared during the previous financial period.

7. Dividend reinvestment plans

Not applicable.

8. Details of associates and joint venture entities

Not applicable

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements were subject to a review by the auditors and the review report is attached as part of the Half-year financial report.

11. Attachments

Details of attachments (if any):

The Half-year financial report of Wellnex Life Limited for the half-year ended 31 December 2025 is attached.

12. Signed

Wellnex Life Limited

ABN 77 150 759 363

Half-year financial report - 31 December 2025

Corporate directory 2

Directors' report 3

Auditor's independence declaration 6

Consolidated Statement of profit or loss and other comprehensive income 7

Consolidated Statement of financial position 8

Consolidated Statement of changes in equity 9

Consolidated Statement of cash flows 10

Notes to the financial statements 11

Directors' declaration 16

Independent auditor's review report to the members of Wellnex Life Limited 17

The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'consolidated entity') consisting of Wellnex Life Limited (referred to hereafter as the 'company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 31 December 2025.

The information in this report should be read in conjunction with the most recent annual financial report, being the report for the year ended 30 June 2025.

Directors

The following persons were directors of Wellnex Life Limited during the whole of the financial half-year and up to the date of this report, unless otherwise stated:

Principal activities

During the financial half-year the principal continuing activities of the consolidated entity consisted of:

Dividends

There were no dividends paid, recommended or declared during the current or previous financial half-year.

Review of operations

Revenue for the period was $12.919 million, an increase of 8% on the prior corresponding period (31 December 2024: $12.0 million), with brand sales comprising 72.3% of the total revenue with the balance coming from IP licensing. During the period, the Company commenced a strategic turnaround program focused on transitioning to a leaner and more agile operating model. This initiative includes the implementation of an enhanced management framework and disciplined capital management, targeting over $1 million in annualised operating savings. As result for the period gross margin increased to 32.1%, an increase of 9.4% on the prior corresponding period. The Group closed Q2 FY26 operating at breakeven, providing a solid platform entering 2HFY26 The Company continues to focus on revenue growth in 2HFY26 and remains focussed on delivering consistent performance with the goal of creating long-term shareholder value.

Pain Away Pain Away maintained market position while improving profitability in a competitive category, delivering $7.0 million in sales (1HFY26), with gross margin improving 7.9%.Pain Away Heat patches scan at stores volumes grew 30.8% in Pharmacy versus 0.2% across all other Heat Patches and 1.4% for the total topical pain category. This result lifted market share of patches format to 19.5% for this period, a 3.8-point gain year-on-year. Roll-ons grew 6% vs the 1.4% total topical pain category in Australia with our two SKUs ranked #1 and #3 ahead of a third roll-on launch by the Company planned in 2HFY2026.Distribution momentum continues, with Priceline launching five new SKUs across Australia, and each of Wellnex's three major pharmacy wholesalers have confirmed four new product launches. Furthermore, Costco Australia and Costco New Zealand will trial an exclusive heat patch in 2HFY2026.

Wakey Wakey/Nighty Night We have taken decisive steps in consolidating some of our underperforming SKUs. We will continue to supply the brands in line with our customer commitments until they are sold or we enter into a discontinuation agreement. We will cease all investments in these areas thereafter.  Wagner Health Liquigesic Wellnex Life launched Australia's first TGA approved soft gel liquid paracetamol product in a jointly owned brand with leading retailer Chemist Warehouse under the Wagner Liquigesic brand. This brand continues to strengthen with increasing brand recognition and revenue. The success of the brand has seen the product offering increased by three new lines pack sizes of mini ibuprofen (20/40/100) that was announced in March 2024. The new products were launched into the market during 2024.The Wagner Liquigesic liquid softgel brand is currently available in 3 products: Paracetamol, Paracetamol and Ibuprofen and Mini Ibuprofen.

Mr Bright Wellnex Life's natural teeth whitening brand is no longer being sold, and the company will be divesting the brand's intellectual property. IP LicensingWellnex Life continues to strengthen its planning discipline and are working with partners to implement a more productive and sustainable operating model focused on commercial value delivery.  Other mattersDuring the period, Wellnex Life initiated a strategic turnaround agenda, including a Board restructure reducing the number of directors from 7 to 3. The Company also formally accepted the resignation of both Joint Chief Executive Officers. Mr Ash Vesali was appointed Executive Chairman, overseeing both the Board and management during the transition period. Upon appointment of suitable Chief Executive Officer in 2HFY26 and completion of the handover process Mr Vesali will transition to the role of Non-Executive Chairman.

Matters subsequent to the end of the financial half-year

No matter or circumstance has arisen since 31 December 2025 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

Rounding of amounts

The company is of a kind referred to in Corporations Instrument 2016/191, issued by the Australian Securities and Investments Commission, relating to 'rounding-off'. Amounts in this report have been rounded off in accordance with that Corporations Instrument to the nearest thousand dollars, or in certain cases, the nearest dollar.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report.

This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the directors

* Relates to cash outflows for transaction costs previously accrued in connection with the capital raising activities undertaken on the ASX and the LSE AIM market in prior periods.

Note 1. General information

The financial statements cover Wellnex Life Limited as a consolidated entity consisting of Wellnex Life Limited and the entities it controlled at the end of, or during, the half-year. The financial statements are presented in Australian dollars, which is Wellnex Life Limited's functional and presentation currency.

Wellnex Life Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

A description of the nature of the consolidated entity's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 27 February 2026.

Note 2. Material accounting policy information

These general purpose financial statements for the interim half-year reporting period ended 31 December 2025 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2025 and any public announcements made by the company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, except for the policies stated below.

New, revised or amending Accounting Standards and Interpretations adopted

The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated entity, other than as disclosed in the financial statements.

Going Concern

The financial report has been prepared on a going concern basis, which contemplates continuity of normal business activities and realisation of assets and liabilities in the ordinary course of business. The going concern of the consolidated entity is dependent upon it maintaining sufficient funds for its operations and commitments.The consolidated entity made a loss after tax of $1.793 million during the half year ended 31 December 2025, incurred net operating cash outflows of $3.142 million and as at 31 December 2025, recorded net current liabilities of $4.252 million.These factors indicate a material uncertainty which may cast significant doubt as to whether the consolidated entity will continue as a going concern and therefore whether it will realise its assets and extinguish its liabilities in the normal course of business and at the amounts stated in the financial report.Notwithstanding these results, the directors believe that the Company will be able to continue as a going concern and accordingly the financial statements have been prepared on a going concern basis, supported by the following reasons:

In the event that the consolidated entity is unable to achieve the outcomes noted above and not be able to continue as a going concern, it may be required to realise its assets at amounts different to those currently recognised, settle liabilities other than in the ordinary course of business and make provisions for other costs which may arise as a result of cessation or curtailment of normal business operations. 

Note 3. Critical accounting judgements, estimates and assumptions

There was no significant or material change in the formulation and usage of estimates and judgments made in preparing these interim financial statements from those applied in preparing the annual report for the year ended 30 June 2025.

Note 4. Operating segments

An operating segment is a component of an entity that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity), whose operating results are regularly reviewed by the entity's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance and for which discrete financial information is available. Management will also consider other factors in determining operating segments such as the existence of a line manager and the level of segment information presented to the board of directors.Revenues of the consolidated entity are recognised at a point in time.

Operating segment information

During the financial year, the Group generated more than 10% of its revenue from five individual customers, with total sales to these customers amounting to $9,907,000 (31 December 2024: $7,358,000). Apart from these, no other customer individually accounted for more than 10% of the Group's revenue.

Geographical information

Note 5. Non-current assets - intangibles

In accordance with AASB 136 Impairment of Assets, the Group assesses at each reporting date whether there is any indication that an asset or cash generating unit may be impaired. During the half year ended 31 December 2025, impairment indicators were identified in relation to the PainAway cash generating unit ("CGU"). Accordingly, an impairment assessment was performed with the assistance of management's valuation expert. The recoverable amount of the Pain Away CGU was determined using a value in use ("VIU") model based on management approved cash flow forecasts covering a five year period. Cash flows beyond the forecast period were extrapolated using a terminal growth rate that does not exceed the long term expected growth rate of the relevant industry. The carrying amount of the CGU includes the Pain Away brand intangible asset together with directly attributable working capital balances.Key assumptions applied in the model include the following: Forecast revenue growth: 9.8% - 14.7%EBITDA margins: 22.5% - 30.4%Terminal growth rate: 2.50%Pre-tax discount rate: 21.5%Based on the assessment performed, the recoverable amount exceeded the carrying amount of the Pain Away CGU and no impairment charge was recognised for the period. Sensitivity analysis was performed on key assumptions and no reasonably possible change would result in an impairment.

Note 6. Current liabilities - Borrowings

Trade and debtor facility

In July 2021, the Company entered into a secured revolving trade and debtor facility with Scottish Pacific, with the key terms of this facility as follows:

Related party loansAmounts due and payable to related parties of the Company are $ 2,969,000. Loans to related parties are unsecured, and during the period a 10% interest rate was placed on the amounts borrowed by the Company. The majority of the loans were extended to a repayment date of 20 April 2026 and carry no equity conversion features and therefore are at terms that the directors consider are no more favourable to the related parties than at market terms. 

Note 7. Non-current liabilities - Borrowings

During the half-year period, the Company entered into Asset Based Loan Agreements for a total facility limit of $5,325,000 with an external financier. As at 31 December 2025, $4,950,000 was drawn down under these facilities. The loans are secured against the assets of the Company and are repayable 24 months following the first advance, bear interest payable of 14% on the funds advanced and a 3% loan establishment fee. As at 31 December 2025 and to the date of this report, there has been no breach of the loan or its covenants.

Note 8. Equity - Issued capital

Movements in ordinary share capital

* Convertible note liabilities which were recorded in the 30 June 2025 financial statements, were settled during the period through the issue of ordinary shares following renegotiated terms. The resulting difference between the carrying amount and the fair value of shares issued was recognised as a gain on extinguishment in profit or loss. 

Note 9. Events after the reporting period

No matter or circumstance has arisen since 31 December 2025 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

In the directors' opinion:

Signed in accordance with a resolution of directors made pursuant to section 303(5)(a) of the Corporations Act 2001.

On behalf of the directors